닥플 플러스
2026 대한조혈모세포이식학회 국제학술대회(ICBMT 2026) - 9월 17일(1일차)
대한조혈모세포이식학회
연수평점 :6점
오프라인
주관
대한조혈모세포이식학회
교육일자
2026-09-17
수강료
200,000원
교육형태
오프라인
등록일시
2026-07-29
교육시간
17시간 20분
연수평점
6점
장소
부산광역시 벡스코
교육종류
내과, 소아청소년과, 진단검사의학과, 병리과
타임테이블
| 날짜 | 시간 | 강의명 | 강사 | 구분 |
|---|---|---|---|---|
| 2026-09-17 | 09:00~09:10 | [구연발표]Distinct Genetic Architecture and Integrated Risk Stratification in Adult ETP-ALL and Other T-ALL | Seonghan Lee(Seoul St. Marys Hospital College of Medicine The Catholic University of Korea) | - |
| 2026-09-17 | 09:10~09:20 | [구연발표]Inotuzumab Ozogamicin as Salvage Therapy Prior to Second Allogeneic Hematopoietic Cell Transplantation Reduces Relapse Without Increasing Non-Relapse Mortality in Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia | Joon Young Hur(Asan Medical Center University of Ulsan College of Medicine) | - |
| 2026-09-17 | 09:20~09:30 | [구연발표]TAL1 Activation Mechanisms Stratify Relapse Risk and Identify a High-Risk Subgroup Unresponsive to HSCT in Pediatric T-ALL | Senlin Zhang(Childrens Hospital of Soochow University) | - |
| 2026-09-17 | 09:30~09:40 | [구연발표]Genomic Landscape and Clinical Outcomes of MTAP Rearrangements in Pediatric T-Cell Acute Lymphoblastic Leukemia: A Retrospective Cohort Study | Shier Cheng(Childrens Hospital of Soochow University) | - |
| 2026-09-17 | 09:40~09:50 | [구연발표]Successful transplant-sparing management of EBF1::PDGFRB-positive Ph-like acute lymphoblastic leukemia using imatinib and CD19 CAR-T therapy with prolonged TKI maintenance | Hina Nakajima(Chiba University Hospital) | - |
| 2026-09-17 | 09:50~10:00 | [구연발표]Clinical Outcomes of Adults with Ph-Positive ALL Treated with Frontline Ponatinib Plus Hyper-CVAD Followed by RTC-Allo-HCT Incorporating ATG/PTCy; Additional Role of Ponatinib Prophylaxis | Jong Hyuk Lee(Incheon St. Marys Hospital College of MedicineIncheon St. Mary's Hospital College of Medicine) | - |
| 2026-09-17 | 09:00~09:10 | [구연발표]Multi-Trajectories of Lipid Profiles and Their Association with Clinical Outcomes in AML Patients Undergoing allo-HSCT | Hongru Chen(Peking University Peoples Hospital) | - |
| 2026-09-17 | 09:10~09:20 | [구연발표]High Frequency of Extramedullary Relapse in Very Late Relapse of Acute Myeloid Leukemia after Allogeneic Hematopoietic Cell Transplantation | Jin-Hee Han(Asan Medical Center) | - |
| 2026-09-17 | 09:20~09:30 | [구연발표]Comparable Post-Transplant Outcomes Following Intensive Chemotherapy versus Hypomethylating Agent plus Venetoclax Before First Allogeneic Hematopoietic Cell Transplantation for Acute Myeloid Leukemia | Hyunkyung Park(Asan Medical Center University of Ulsan College of Medicine) | - |
| 2026-09-17 | 09:30~09:40 | [구연발표]HCT-CI Failed to Predict Survival Outcomes in Elderly Patients with AML/MDS Undergoing Haploidentical Transplantation | Yuqian Sun(Peking University Peoples Hospital) | - |
| 2026-09-17 | 09:40~09:50 | [구연발표]Venetoclax Plus Hypomethylating Agents for Acute Myeloid Leukemia Relapsing After Allogeneic Hematopoietic Cell Transplantation | Jiseon Park(Asan Medical Center University of Ulsan College of Medicine) | - |
| 2026-09-17 | 09:50~10:00 | [구연발표]Efficacy and Safety of Venetoclax and Azacitidine Maintenance in Reducing Relapse After Haploidentical HSCT for Pediatric AML: A Retrospective Two-Center Cohort Study | He Hongbo(Beijing Childrens Hospital) | - |
| 2026-09-17 | 09:00~09:10 | [구연발표]Discovery of a Novel Quiescence-Associated Marker of Top-Tier Hematopoietic Stem Cells in Umbilical Cord Blood by Transcriptomic Profiling | Dong-Yeop Shin(Seoul National University Hospital College of Medicine) | - |
| 2026-09-17 | 09:10~09:20 | [구연발표]Longitudinal Single-Cell Profiling of Bone Marrow Reveals Intercellular Communication Rewiring in Chronic Graft-versus-Host Disease | Jong Hyuk Lee(Incheon St. Marys Hospital College of Medicine) | - |
| 2026-09-17 | 09:20~09:30 | [구연발표]Ectopic EBV Infection in T Cells Identifies Reduced Therapeutic Responsiveness and Immune Dysfunction After Allogeneic Hematopoietic Stem Cell Transplantation | Zhifan Zhao(Peking University) | - |
| 2026-09-17 | 09:30~09:40 | [구연발표]An Integrated Single-Cell Atlas of Acute Lymphoblastic Leukemia Defines Malignant-Core State Architecture Across Clinical and Molecular Contexts | Javad Alizargar(National Taipei University of Nursing) | - |
| 2026-09-17 | 09:40~09:50 | [구연발표]HLA Structural Profiles Identified by Protein Language Models Predict Graft Failure in Haploidentical Transplantation | Rui Ma(Peking University Peoples Hospital) | - |
| 2026-09-17 | 09:50~10:00 | [구연발표]Tumor Necrosis Factor is a Growth Factor for Mesenchymal Stromal Progenitor Cells | Aleksei Bigildeev(Moscow institute for physics and technology (MIPT)) | - |
| 2026-09-17 | 09:00~09:10 | [구연발표]Model-Predicted Antithymocyte Globulin Exposure And Clinical Outcomes After Haploidentical Peripheral Blood Stem Cell Transplantation In Adult Acute Myeloid Leukemia | Daehun Kwag(Catholic Hematology Hospital Seoul St. Mary) | - |
| 2026-09-17 | 09:10~09:20 | [구연발표]Older Matched Sibling Donors Remain a Favorable Option in Allogeneic Hematopoietic Stem Cell Transplantation for Aplastic Anemia: Impact of Donor Age Across Donor Types | So Yeon Park(Seoul St. Marys Hospital College of Medicine) | - |
| 2026-09-17 | 09:20~09:30 | [구연발표]Pegylated versus daily G-CSF for peripheral blood stem cell mobilization in allogeneic hematopoietic cell transplantation donors | Ryo Sato(Yamagata University) | - |
| 2026-09-17 | 09:30~09:40 | [구연발표]Sequential Haploidentical-Cord Blood Hematopoietic Stem-Cell Transplantation With PT-Cy/Flu in Pediatric Acute Leukemia | Zhilin Hu(Shenzhen Children) | - |
| 2026-09-17 | 09:40~09:50 | [구연발표]The Comparison of Bone Marrow plus Peripheral Blood versus Peripheral Blood as Graft Source in Haploidentical Stem Cell Transplantation for Older Patients | Wei Zhao(Peking University Peoples Hospital) | - |
| 2026-09-17 | 09:50~10:00 | [구연발표]Successful Multi-Modal Management of Refractory CMV-Associated Hemophagocytic Lymphohistiocytosis and Idiopathic Pneumonia Syndrome Following HLA-Mismatched Bone Marrow Transplantation for Severe Aplastic Anemia | Yuichi Kobayashi(Chiba University) | - |
| 2026-09-17 | 10:00~10:30 | 휴식 | - | - |
| 2026-09-17 | 10:30~11:10 | Current Real World Practice to Optimize Outcomes of CAR T Cell Therapy for Pediatric ALL | Stephen A. Grupp(Childrens Hospital of Philadelphia) | - |
| 2026-09-17 | 11:10~11:50 | Eliminating GVHD Prophylaxis: A New Era of Sequential CAR-T and Allogeneic HSCT | He Huang(The First Affiliated Hospital Zhejiang University School of Medicine) | - |
| 2026-09-17 | 11:50~12:00 | 휴식 | - | - |
| 2026-09-17 | 12:00~12:40 | Optimizing cGVHD Management After Ruxolitinib Failure: The Role of Belumosudil in Clinical Practice | Jia Chen(The First Affiliated Hospital of Soochow University) | - |
| 2026-09-17 | 12:00~12:40 | Maintaining Relative Dose Intensity in Elderly DLBCL: Clinical Strategies with Pegfilgrastim | Hyunsoo Cho(Seoul National University Hospital) | - |
| 2026-09-17 | 12:00~12:40 | Real World Evidence on the Efficacy and Safety of Iptacopan in PNH Management | Silvia Park(College of Medicine The Catholic University of Korea) | - |
| 2026-09-17 | 12:40~13:00 | 휴식 | - | - |
| 2026-09-17 | 13:00~13:40 | Beyond Immunosuppression: Enhancing Tissue Resilience to Mitigate GVHD | Pavan Reddy(Dan L. Duncan Comprehensive Cancer Center) | - |
| 2026-09-17 | 13:40~14:20 | Immunologic Mechanisms and Modulation of Chronic Graft-Versus-Host Disease | Bruce R. Blazar(University of Minnesota) | - |
| 2026-09-17 | 14:20~14:30 | 휴식 | - | - |
| 2026-09-17 | 14:30~15:00 | Advances in Ex Vivo T Cell Depletion | Margaret MacMillan(University of Minnesota) | - |
| 2026-09-17 | 15:00~15:30 | Selective T cell Depletion and Enrichment | Marie Bleakley(Fred Hutchinson Cancer Center) | - |
| 2026-09-17 | 15:30~16:00 | Optimizing T-Cell Modulation in Adult ALL Transplantation: ATG, PTCy, and Donor-Specific GVHD Control | Jae-Ho Yoon(College of Medicine The Catholic University of Korea) | - |
| 2026-09-17 | 14:30~15:00 | Biomarkers and Immune Fitness Shaping Outcomes of Immune Effector Cell Therapies | Rizwan Romee(Dana-Farber Cancer Institute) | - |
| 2026-09-17 | 15:00~15:30 | In Vivo CAR-T Engineering for Lymphoid Malignancies | Heng Mei(Union Hospital Tongji Medical College Huazhong University of Science and Technology) | - |
| 2026-09-17 | 15:30~16:00 | Overcoming Resistance in T-cell Malignancies: From Phase 1 Study of CD5-targeted Allogeneic CAR-NK Cells | Dok Hyun Yoon(University of Ulsan College of Medicine) | - |
| 2026-09-17 | 14:30~15:00 | Virus-specific T Cells for Adoptive Immunotherapy | Susan E. Prockop(Dana-Farber Cancer Institute) | - |
| 2026-09-17 | 15:00~15:30 | Strategies for Determining Treatment Flow of CAR T-Cell Therapy and HSCT in Pediatric ALL | Krzysztof Kalwak(Wroclaw Medical University) | - |
| 2026-09-17 | 15:30~16:00 | Clinical Applications of Donor Lymphocyte Infusion in Pediatric Malignancies | Hee Young Ju(Sungkyunkwan University School of Medicine) | - |
| 2026-09-17 | 14:30~15:00 | Management of Poor Graft Function in Chilren | Eun Sang Yi(Korea University College of Medicine) | - |
| 2026-09-17 | 15:00~15:30 | Donor Lymphocyte Infusion (DLI) in 2026: Indications, Dosing, and GVHD Trade-offs | Hyunkyung Park(University of Ulsan College of Medicine) | - |
| 2026-09-17 | 15:30~16:00 | Cellular Support Beyond the Graft: Integrative Strategis after Allogeneic HSCT | Koen Van Besien(Case Western Reserve University School of Medicine) | - |
| 2026-09-17 | 16:00~16:10 | 휴식 | - | - |
| 2026-09-17 | 16:10~16:40 | Poster | - | - |
| 2026-09-17 | 16:40~16:50 | 휴식 | - | - |
| 2026-09-17 | 16:50~17:15 | Germline Traits and Donor Selection for Allo-HCT: on Overview and the Paradigm of DDX41 | Carmelo Gurnari(University of Tor Vergata) | - |
| 2026-09-17 | 17:15~17:40 | Which Donor Should We Use in the Absence of a Matched Sibling in Aplastic Anemia? | Juan Montoro(La Fe University and Polytechnic Hospital) | - |
| 2026-09-17 | 17:40~18:05 | Clonal Hematopoiesis in Hematopoietic Stem Cell Transplantation | Youngil Koh(Seoul National University College of Medicine) | - |
| 2026-09-17 | 18:05~18:30 | Hematopoietic Stem Cell Donor Selection in 2026: Evolving Perspectives and Current Challenges | Yunsuk Choi(University of Ulsan College of Medicine) | - |
| 2026-09-17 | 16:50~17:20 | Flow Cytometric MRD for AML: Updates in 2026 | Jacqueline Cloos(Amsterdam UMC) | - |
| 2026-09-17 | 17:20~17:50 | Targeting Residual Disease after Transplant: The Convergence of HCT and Engineered Cellular Therapies | Ran Reshef(Columbia University Irving Medical Center) | - |
| 2026-09-17 | 17:50~18:20 | Clinical Experience with NGS-based Chimerism Analyses in HSCT Patients | Saeam Shin(Yonsei University College of Medicine) | - |
| 2026-09-17 | 16:50~17:20 | Longitudinal Single-Cell Dissection of Venetoclax Resistance in Secondary AML | Semin Lee(UNIST) | - |
| 2026-09-17 | 17:20~17:50 | Improving Post-transplant Immunological Outcome in AML by Modulating VISTA | Tae Kon Kim(Vanderbilt University Medical Center) | - |
| 2026-09-17 | 17:50~18:20 | Immune Escape as a Mechanism of Post-transplant Relapse | Jaroslaw P. Maciejewski(Taussig Cancer Institute) | - |
비고
회원 150,000원, 비회원 200,000원, 기타 80,000원
문의처
담당자
김혜진
연락처
02-516-6581
이메일
bmt@kams.or.kr